In a clinical trial that was stopped early, researchers found that patients with ventilator-associated bacterial pneumonia who took 7 days of Doribax had a higher 28-day all-cause mortality of 23% compared to 16.7 % in those who took Primaxin (imipenem/cilastatin ). The cure rates were also lower in the Doribax arm which led the FDA to approve changes to the drug label. The package insert now includes a warning on using Doribax to treat ventilator associated bacterial pneumonia. Doribax is still FDA-approved to treat complicated intra-abdominal infections and complicated urinary tract infections.
What medications would you recommend to treat ventilator associated bacterial pneumonia?
Image courtesy of [dream designs]/FreeDigitalPhotos.net